MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy

Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.

[1]  Robert J Gillies,et al.  Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. , 2005, Neoplasia.

[2]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[3]  A. Holodny,et al.  MRI of high-grade glial tumors: correlation between the degree of contrast enhancement and the volume of surrounding edema , 1997, Neuroradiology.

[4]  Susan M. Chang,et al.  A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2006, Neuro-oncology.

[5]  Paul S Mischel,et al.  MR imaging correlates of survival in patients with high-grade gliomas. , 2005, AJNR. American journal of neuroradiology.

[6]  M. J. van den Bent,et al.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2004, Neurology.

[7]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[8]  P. Mwinzi,et al.  Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis , 2005, Journal of Neuroimmunology.

[9]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Di Lorenzo,et al.  hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines , 2005, British Journal of Cancer.

[11]  H. Mehdorn,et al.  Expression of VEGF and its receptors in different brain tumors , 2005, Neurological research.

[12]  F. Kabbinavar,et al.  Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer , 2004, Techniques in Coloproctology.